MalaysiaTuberculosis profile
Population  2014 30 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.4 (1.3–3.7) 8 (4.5–12)
Mortality (HIV+TB only) 0.62 (0.38–0.93) 2.1 (1.3–3.1)
Prevalence  (includes HIV+TB) 40 (19–69) 135 (63–232)
Incidence  (includes HIV+TB) 31 (25–37) 103 (83–124)
Incidence (HIV+TB only) 2.2 (1.8–2.6) 7.3 (5.9–8.8)
         
Case detection, all forms (%) 78 (65–96)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.4 (0.24–0.63) 1.1 (0.24–3.3)
MDR-TB cases among notified pulmonary
TB cases
80 (48–120) 20 (4–56)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 14 099   749
Pulmonary, clinically diagnosed 5 743   300
Extrapulmonary 3 055   108
       
Total new and relapse 24 054    
Previously treated, excluding relapses 657    
Total cases notified 24 711    
Among 24 054 new and relapse cases:
691 (3%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 5 171 (37%) 298 (16%) 14 701
Laboratory-confirmed RR-/MDR-TB cases     319
Patients started on MDR-TB treatment ***     60
TB/HIV 2014 Number (%)
TB patients with known HIV status 21 698 (88)
HIV-positive TB patients 1 468 (7)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 109 (7)
HIV-positive TB patients on antiretroviral therapy (ART) 453 (31)
HIV-positive people screened for TB 4 790  
HIV-positive people provided with IPT 2 063  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (76) 23 346
Previously treated cases, excluding relapse, registered in 2013 (46) 654
HIV-positive TB cases, all types, registered in 2013 (51) 1 510
RR-/MDR-TB cases started on second-line treatment in 2012 (30) 74
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 2.6
Culture (per 5 million population) 6.5
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 15
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-27 Data: www.who.int/tb/data